Genome-wide analysis for Severe Aortic Stenosis
Not Applicable
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0005539
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
1. Men or Women aged 19 and over
2. Subject who have been diagnosed with aortic valve stenosis disease by cardiac ultrasonography from IRB approval planned percutaneous or surgical aortic valve replacement.
Exclusion Criteria
In case of refuze of study paricipaint and collect of human objects in blood samples.
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Death of all causes after aortic valve replacement.
- Secondary Outcome Measures
Name Time Method Heart death, Myocardial infarction, Stroke and transient ischemic attack, Bleeding, Vascular treatment or Operation and associated complications, Acute kidney disease, Insert pacemaker, Complications from other percutaneous aortic valve replacements, Artificial valve failure, Structural abnormality of cardiac valve, NYHA rated at 30 Days after valve replacement/1 Year, 30 days/1 year valve area after valve replacement, Atrial fibrillation